- Conditions
- Undernutrition
- Interventions
- Nutrition Intervention
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1705–1728
of 12,241
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Volunteers
- Interventions
- Risk Assessment App, Audio Recording - Sleep, Surveys, Audio Recording - Exercise, Text message reminders, Text Message Survey
- Behavioral · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 30 Years to 64 Years
- Enrollment
- 554 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Complex Partial Seizures
- Interventions
- vigabatrin
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
- Interventions
- flow cytometry, laboratory biomarker analysis, Data Collection
- Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2019
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Alzheimer Disease
- Interventions
- AR1001, Placebo
- Drug
- Lead sponsor
- AriBio Co., Ltd.
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 1,535 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 75
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 62 more
- Conditions
- Multiple Sclerosis, Fatigue
- Interventions
- Online Program for Fatigue
- Device
- Lead sponsor
- Accelerated Cure Project for Multiple Sclerosis
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 6
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland • Waltham, Massachusetts + 3 more
- Conditions
- Patients With Schizophrenia and Acute Agitation
- Interventions
- Inhaled loxapine 5 mg, Inhaled loxapine 10 mg, Inhaled placebo
- Drug
- Lead sponsor
- Alexza Pharmaceuticals, Inc.
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Schizophrenia
- Interventions
- Abilify MyCite®
- Combination Product
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 277 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 68
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 55 more
- Conditions
- Wet Age-related Macular Degeneration
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 557 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 65
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 60 more
- Conditions
- Trauma Chest, Pediatric ALL
- Interventions
- Not listed
- Lead sponsor
- Sutter Health
- Other
- Eligibility
- 0 Years to 21 Years
- Enrollment
- 1,020 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Drug Interactions, Primary Prevention, Cardiometabolic Syndrome, LDL-Cholersterol Lowering, Polypharmacy
- Interventions
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Urinary Bladder, Overactive, Incontinence, Urge, Incontinence, Urinary, Urinary Urge Incontinence, Urinary Frequency More Than Once at Night, Nocturia
- Interventions
- OnabotulinumtoxinA 100 UNT
- Drug
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Tampa, Florida
- Conditions
- Breast Cancer
- Interventions
- therapeutic conventional surgery, whole breast irradiation
- Procedure · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2023
- U.S. locations
- 350
- States / cities
- Hot Springs, Arkansas • Dublin, California • Emeryville, California + 216 more
- Conditions
- Melanoma
- Interventions
- Not listed
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 408 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 66
- States / cities
- Muscle Shoals, Alabama • Hot Springs, Arkansas • Long Beach, California + 59 more
- Conditions
- Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
- Interventions
- CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
- Drug
- Lead sponsor
- Cyteir Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 16
- States / cities
- San Francisco, California • Stanford, California • Denver, Colorado + 12 more
- Conditions
- Lumbar Spinal Stenosis, Lumbar Spinal Instability, Lumbar Spine Degeneration
- Interventions
- Standard analgesia use [Oxygen], Standard analgesia use [Hydromorphone], Standard analgesia use [Volatile Anesthesia], Standard analgesia use [Fentanyl], Multi-modal pain management [Acetaminophen + Gabapentin], Multi-modal pain management [Fentanyl], Multi-modal pain management [Intravenous Ketamine], Multi-modal pain management [Valium + Gabapentin]
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Small Intestine Cancer
- Interventions
- cyclophosphamide, allogeneic bone marrow transplantation, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 50 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Multiple Sclerosis
- Interventions
- Siponimod
- Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- Female only
- Enrollment
- 867 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2032
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- TBI (Traumatic Brain Injury)
- Interventions
- Infrascanner
- Device
- Lead sponsor
- InfraScan, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 431 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Cincinnati, Ohio • Philadelphia, Pennsylvania + 1 more
- Conditions
- Burnout, Professional
- Interventions
- MINDI mindfulness curriculum, Control
- Other
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 358 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carfilzomib, Laboratory Biomarker Analysis, Melphalan
- Procedure · Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Multiple Sclerosis
- Interventions
- RPC1063
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 2,494 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Berkeley, California • Fresno, California + 15 more
- Conditions
- Asthma
- Interventions
- GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
- Biological · Drug · Device
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,717 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 119
- States / cities
- Birmingham, Alabama • Scottsboro, Alabama • Litchfield Park, Arizona + 94 more
- Conditions
- Multiple Myeloma
- Interventions
- pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 455 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota